Drug Discovery Chemistry Europe 2025

Meet Novalix at the 2nd Annual Drug Discovery Chemistry 2025, a conference for drug discovery scientists working in pharma, biotech, and academia. Organized by Cambridge Healthtech Institute (CHI), this edition will focus on ‘Optimising Small Molecules for Tomorrow’s Therapeutics’.

“Identification of a submicromolar BRD4 PROTAC degrader from a moderately potent DEL Hit: Harnessing the synergy of DEL and PROTAC technologies”

We are very happy to share that we will contribute to the scientific program with a poster presentation. Don’t miss the session animated by Hugues Prevet, PhD, Senior Scientist Drug Discovery.
He will present the development of a submicromolar BRD4 PROTAC directly derived from a moderately potent DEL hit, showcasing the synergy between DEL and PROTAC technologies in targeted protein degradation.

Abstract:
We identified a BRD4-targeting PROTAC degrader with submicromolar degradation potency derived directly from a moderately potent hit identified via a DNA-encoded library (DEL) screen using our NovaDEL platform. This underscores the potential of PROTACs to achieve efficient degradation from micromolar binders, a concept rarely demonstrated. This finding reinforces the viability of leveraging such binders in induced proximity strategies and opens new avenues for therapeutic innovation and drug discovery.

About Drug Discovery Chemistry Europe

Both in-person and online, the event offers plenary keynote sessions and a plenary panel discussion featuring insights from venture capitalists. Talks will cover AI-driven lead optimization, fragment-based design, DEL screening, protein degradation, and more, offering attendees a practical view of how today’s most promising strategies are being applied across therapeutic areas.

Meet us at Booth No.6

Come and meet our team at our Booth No.6. Discover how we can support each stage of your drug discovery program. Just set a meeting to discuss on-site with our team: